Compounds For Use In The Treatment Of Diseases

Abstract

The present invention relates to a compound of the general formula (III):

1 . A compound of the general formula (III): 
       
         
           
           
               
               
           
         
         for use in the treatment and/or prevention of a disease related to eosinophil peroxidase, wherein 
         R 1  is CH 2 , NH, O, S or a single bond, 
         R 2 , R 3 , R 4 , R 5  and R 6  independently of one another are H, OH, F, Cl, Br, I or a C 1  to C 5  alkyl group, and 
         R 1  is H, OH, NH 2 , NH—NH 2  or CH 3 . 
       
     
     
         2 . The compound according to  claim 1 , wherein R 1  is NH and R 7  is NH—NH 2  and said compound has the general formula (IV). 
       
         
           
           
               
               
           
         
       
     
     
         3 . The compound according to  claim 1 , wherein said C 1  to C 5  alkyl group is selected from the group consisting of CH 3  and CH 2 CH 3 . 
     
     
         4 . The compound according to  claim 1 , wherein R 1  is CH 2 , NH, O or S, R 2  is F or H, R 3  is Cl, Br or H, R 4  is Cl, F, CH 3  or H, R 5  and R 6  are H, and R 7  is OH or NH—NH 2 . 
     
     
         5 . The compound according to  claim 1 , wherein said compound is selected from the group consisting of 2-fluoro-phenylaminoethane-hydrazide, 4-fluoro-phenylaminoethane-hydrazide, 2,4-di-fluoro-phenylaminoethane-hydrazide, 4-chloro-phenylaminoethane-hydrazide, 3-chloro-4-fluoro-phenylaminoethane-hydrazide, 3-bromo-4-fluoro-phenylaminoethane-hydrazide, 4-methyl-phenylaminoethane-hydrazide, phenylaminoethane-hydrazide, 2-[(4-chlorophenyl)sulfanyl]acetohydrazide, 2-(4-fluorophenoxy)acetohydrazide, 2-(2-bromophenoxy)acetohydrazide, N-(2-fluorophenyl)glycine, 2-[(4-chlorophenyl)amino]acetic acid, and 3-(2-hydroxyphenyl)propanohydrazide. 
     
     
         6 . The compound according to  claim 1 , wherein the disease related to eosinophil peroxidase is selected from the group consisting of bronchial asthma, multiple sclerosis, cystic fibrosis, ulcerative colitis, Crohn's disease, rhinitis, endometriosis, sinusitis, eosinophilic esophagitis, Shulman's syndrome (eosinophilic fasciitis), endocarditis, Churg-Strauss syndrome, dermatoses, herpes gestationis, eosinophilic dermatosis, Hand-Schüller-Christian disease (ASCD), cardiovascular diseases, endocarditis and hypertension due to inflammatory processes of the vascular walls. 
     
     
         7 . The compound according to  claim 1 , wherein said compound is provided in an intravenous, intracavitary, oral, intraperitoneal, inhalation or topical dosage form. 
     
     
         8 . The compound according to  claim 1 , wherein said compound is provided in the form of an infusion, tablet, capsule, cream, gel, emulsion or patch. 
     
     
         9 . The compound according to  claim 1 , wherein said compound is administered at an amount of 0.01 to 2,000 mg/kg of body weight. 
     
     
         10 . A pharmaceutical composition comprising at least one compound according to  claim 1 , for the treatment of a disease related to eosinophil peroxidase. 
     
     
         11 . The pharmaceutical composition according to  claim 10 , wherein said disease is selected from the group consisting of bronchial asthma, multiple sclerosis, cystic fibrosis, ulcerative colitis, Crohn's disease, rhinitis, endometriosis, sinusitis, eosinophilic esophagitis, Shulman's syndrome (eosinophilic fasciitis), endocarditis, Churg-Strauss syndrome, dermatoses, herpes gestationis, eosinophilic dermatosis, Hand-Schüller-Christian disease (ASCD), cardiovascular diseases, endocarditis and hypertension due to inflammatory processes of the vascular walls. 
     
     
         12 . The pharmaceutical composition according to  claim 10 , wherein said compound is provided in an intravenous, intracavitary, oral, intraperitoneal, inhalation or topical dosage form. 
     
     
         13 . The pharmaceutical composition according to  claim 10 , wherein said compound is provided in the form of an infusion, tablet, capsule, cream, gel, emulsion or patch. 
     
     
         14 . Use of a compound according to  claim 1  for the manufacture of medication for the treatment and/or prevention of a disease related to eosinophil peroxidase. 
     
     
         15 . Use of a compound according to  claim 1  for inhibition of eosinophil peroxidase. 
     
     
         16 . The compound according to  claim 2 , wherein said C 1  to C 5  alkyl group is selected from the group consisting of CH 3  and CH 2 CH 3 . 
     
     
         17 . The compound according to  claim 2 , wherein R 1  is CH 2 , NH, O or S, R 2  is F or H, R 3  is Cl, Br or H, R 4  is Cl, F, CH 3  or H, R 5  and R 6  are H, and R 7  is OH or NH—NH 2 . 
     
     
         18 . The compound according to  claim 3 , wherein R 1  is CH 2 , NH, O or S, R 2  is F or H, R 3  is Cl, Br or H, R 4  is Cl, F, CH 3  or H, R 5  and R 6  are H, and R 7  is OH or NH—NH 2 . 
     
     
         19 . The pharmaceutical composition according to  claim 1 , wherein said disease is an inflammatory disease.